Valuation dashboard for Novartis AG (NVS) with P/E 22.79, P/B 8.15, EV/EBITDA 15.28 and dividend yield 2.80%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
Analysis Summary
Novartis AG reported revenue of $54.81B in the most recent fiscal year, growing at a 5-year CAGR of 1.9%. Net income reached $14.06B, with a 11.7% 5-year CAGR.
Trailing-twelve-month margins: gross margin 74.3%, operating margin 30.5%, net margin 18.1%.
At $151.12 (closing price, October 29, 2026), NVS trades at a P/E of 22.79 and an ROE of 24.24%. Market capitalisation stands at $287.2B, placing it among large-cap names.
Balance sheet quality for NVS: current ratio of 1.1. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 22.79 |
| Price / Book | 8.15 |
| EV / EBITDA | 15.28 |
| Dividend Yield | 2.80% |
Valuation Models
| DCF Fair Value | $256.69 |
| vs Current Price | +69.9% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| NVS | Novartis AG | $287.2B | 22.79 | 8.15 | 24.2% |
| MRK | Merck & Co., Inc. | $361.0B | 117.06 | 8.71 | 6.6% |
| GILD | Gilead Sciences, Inc. | $205.3B | -26.6% | ||
| SNY | Sanofi | $103.3B | 23.29 | 1.32 | 5.5% |
| JNJ | Johnson & Johnson | $662.5B | 41.72 | 8.14 | 19.6% |
| ABBV | AbbVie Inc. | $514.2B | 81.98 | -136.5% | |
| AZN | AstraZeneca PLC | $270.5B | 26.19 | 5.36 | 21.7% |
| NVO | Novo Nordisk A/S | $172.9B | 9.65 | 5.07 | 59.1% |
Price
| Price | $151.12 (closing price, October 29, 2026) |
| Market Cap | $287.2B |
| Exchange | NYSE |
| Country | CH |
Profitability
| Return on Equity | 24.24% |
| Return on Invested Capital | 13.96% |
| Return on Assets | 8.43% |
| Gross Margin | 74.30% |
| Operating Margin | 30.47% |
| Net Margin | 18.06% |
Related companies: MRK · GILD · SNY · JNJ · ABBV · AZN · NVO · PFE
Explore sector: Healthcare · Drug Manufacturers - General
More sections of NVS: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks